Nature Communications 에 기재된 'Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumor effects
systemic administration.' 논문이 F1000Prime 에 Article Recommendations 로 highlight 되었습니다.
While antibody administration has become entrenched as a viable therapeutic option, especially for oncologic
applications, targets have been limited to extracellular components due to inability to traverse the plasma membrane.
Shin et al. describe a novel methodology that targets monoclonal antibodies to a cytoplasmic compartment by the
addition of a "homing peptide" that binds to a tumor-associated integrin allowing for internalization with eventual
endosomal escape into the cytoplasm demonstrating activity against a Ras mutant, providing proof of principle for
this concept. While these "internalizing" MAbs (iMAbs) currently suffer from poor endosomal escape and a short half-
life in circulation, these deficiencies appear more as technical concerns, rather than fundamental impediments.
The ability to selectively direct MAbs to cytoplasmic targets could herald a new technical approach to address a wide
range of medical conditions.
Recommended by Michael Kurilla and Randall Kincaid.